PCI Biotech starts dosing in Phase I extension study for bile duct cancer
Norwegian biopharmaceutical firm PCI Biotech has started dosing patients in a Phase I extension study with fimaCHEM to treat inoperable perihilar bile duct cancer.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Bile | Bile Duct Cancer | Biotechnology | Cancer | Cancer & Oncology | Cholangiocarcinoma | Norway Health | Study